‘Really regrettable’, says NICE over decision not to approve breast cancer drug Enhertu

Dr Sam Roberts. Credit: UK Parliament

By Sarah Lowden

Deciding not to approve the drug Enhertu for advanced HER2-low breast cancer patients in England is “really regrettable” but due process has been followed, the National Institute for Health and Care Excellence has told MPs.

In March, NICE announced that the cost of trastuzumab deruxtecan - sold under the brand name Enhertu - was too high in relation to its benefits.